MOUNTAIN VIEW, Calif., March 16 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced the release of the latest version of the WinNonlin(R) Validation Suite(TM). The WinNonlin Validation Suite enables rapid and reliable validation of new and upgraded installations of WinNonlin using a battery of automated tests. In addition, the Validation Suite provides templates for validation life cycle documents, such as a Validation Plan, Test Plan, and Validation Summary Report, and inserts automated test results into a Validation Run Report.
With the WinNonlin Validation Suite much of the most difficult and error-prone work in validation is automated away. Most of the test scripts are automated, with the output being automatically compared to reference output. This automated process can reduce the validation effort by several man-weeks and eliminates potential errors introduced by manually comparing test results. The reference output was created on a Pharsight reference workstation and compared favorably to results obtained from analyses with independent tools (e.g., SAS). This reference output verification is summarized in the Computational Models Validation Report that is included in the WinNonlin Validation Suite.
"A key benefit of the WinNonlin Validation Suite is the shortened path to re-validation when upgrading WinNonlin," said Dan Weiner, Ph.D., senior vice president for software products at Pharsight Corporation. "The Validation Suite allows one to leverage the structure of a previous validation with the rapid automated re-testing of the system. This makes it easier to keep the validation status of WinNonlin up to date after new releases of Windows or the newly released IVIVC Toolkit(TM) for WinNonlin."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Forward Looking Statements
The statements in this press release related to the design and performance of the Pharsight WinNonlin and WinNonlin Validation Suite products are forward looking statements. Forward-looking statements are inherently speculative, and actual results may differ materially from Pharsight's expectations due to a variety of factors, including: the time saved by using the product; and customers may not perceive the benefits of the product to be the same as Pharsight believes them to be. Other risk factors relating to Pharsight are disclosed in the company's most recent Form 10-Q filed with the Securities and Exchange Commission on February 12, 2007. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements.
Registered Trademarks and Trademarks
Pharsight, WinNonlin, and WinNonlin Validation Suite are registered trademarks or trademarks of Pharsight Corporation.
Pharsight CorporationCONTACT: Investors, Douglas Sherk or Jennifer Beugelmans, +1-415-896-6820,or Media, Steve DiMattia, +1-646-277-8706, all of EVC Group, for PharsightCorporation
Web site: http://www.pharsight.com//
